KBC Securities - Hyloris Pharmaceuticals (HYL) Hyloris FIRST LOOK: US deal on tranexamic acid RTU with Avenacy

Report

KBC Securities

Jacob Mekhael ...

Thomas Vranken

Hyloris FIRST LOOK: US deal on tranexamic acid RTU with Avenacy

Hyloris announced an exclusive license and supply agreement with Avenacy for tranexamic acid RTU in the US. The deal is set up as a profit sharing agreement with commercialisation expected to start in 2025. We reiterate our € 5 TP and Hold rating.

27/12/2024 1 EN

Underlying

Hyloris Pharmaceuticals

See profile

BE0974363955 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Thomas Vranken

Other Reports on these Companies

KBC Securities

Morning Notes : AALB NA, ARGX BB, HYL BB

: AALB NA, ARGX BB, HYL BB

December 27, 2024 December 27, 2024 1 EN

KBC Securities

Hyloris Valacyclovir oral suspension deal with Rosemont, appoints new CFO

Hyloris announced an exclusive license and supply agreement with Rosemont Pharmaceuticals for its Valacyclovir oral suspension in the US. In addition, the company appointed a new CFO, Christophe Maréchal, who previously served as CFO and co-CEO of Mithra. We reiterate our € 5 TP and HOLD rating.

December 9, 2024 December 9, 2024 1 EN

Morning Notes : AALB NA, ARGX BB, HYL BB

: AALB NA, ARGX BB, HYL BB

December 27, 2024 December 27, 2024 1 EN

Thomas Vranken

Thomas Vranken

argenx FIRST LOOK: CIDP approvals now include Japan

argenx announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the application for Vyvdura (SC efgartigimod) in adults with CIDP. Following gMG and ITP, CIDP represents the third indication for Vyvgart/Vyvdura in the country, and obtained self-administration in this geography as well. We reiterate our € 615 TP and Accumulate rating.

December 27, 2024 December 27, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Hyloris FIRST LOOK: US deal on tranexamic acid RTU with Avenacy

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : AALB NA, ARGX BB, HYL BB

Hyloris Valacyclovir oral suspension deal with Rosemont, appoints new CFO

Morning Notes : AALB NA, ARGX BB, HYL BB

argenx FIRST LOOK: CIDP approvals now include Japan

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe